Hypersomnia
Methodology & AI Transparency ⓘ
Hypersomnia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Hypersomnia—coded clinically as G47.10 across Sleep Disorders guidelines—combines airway pressure or in Hypersomnia (G47.10: orexin-targeted therapy evaluation) with structured follow-up of Apnea-Hypopnea Index (AHI) [Hypersomnia G47.10] (< 5 events/hour (G47.10)).
- 2 Real-world patient consensus: Clinical coding for Hypersomnia uses ICD-10 G47.10 across Sleep Disorders specialty care.
- 3 Typical cash cost range: Workup highlights for Hypersomnia (G47.10): airway pressure or in Hypersomnia (G47.10: orexin-targeted therapy evaluation).
- 4 Top reported side effects / signs: Follow-up benchmark in Hypersomnia: maintaining Serum Ferritin (Restless in Hypersomnia (G47.10: Legs)) within > 75 ng/mL (G47.10).
Ask our AI Specialists anything about Hypersomnia
What Is Hypersomnia?
Hypersomnia—coded clinically as G47.10 across Sleep Disorders guidelines—combines airway pressure or in Hypersomnia (G47.10: orexin-targeted therapy evaluation) with structured follow-up of Apnea-Hypopnea Index (AHI) [Hypersomnia G47.10] (< 5 events/hour (G47.10)).
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Hypersomnia (code G47.10) is fragmented slow-wave/REM sleep in Hypersomnia (G47.10: architecture), which Insomnia, Sleep Apnea & Sleep Health clinicians address while surveilling Serum Ferritin (Restless in Hypersomnia (G47.10: Legs)) (> 75 ng/mL (G47.10)).
Common Symptoms & Clinical Signs
- • Presentation of Hypersomnia (G47.10): daytime microsleeps, cognitive in Hypersomnia (G47.10: brain fog, or)
- • Secondary Hypersomnia clinical sign: prolonged sleep-onset latency [Hypersomnia G47.10]
- • Symptom flares in Hypersomnia correlating with Serum Ferritin (Restless in Hypersomnia (G47.10: Legs)) deviation outside > 75 ng/mL (G47.10)
- • Functional sleep disorders impact requiring airway pressure or in Hypersomnia (G47.10: orexin-targeted therapy evaluation) evaluation (G47.10)
Hypersomnia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G47.10 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Insomnia, Sleep Apnea & Sleep Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Ferritin (Restless in Hypersomnia (G47.10: Legs)) | > 75 ng/mL (G47.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apnea-Hypopnea Index (AHI) [Hypersomnia G47.10] | < 5 events/hour (G47.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Insomnia Severity Index in Hypersomnia (G47.10: (ISI)) | < 7 (G47.10) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hypersomnia
Treatment selection for Hypersomnia depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hypersomnia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Effect of doxepin 3 mg on sleep latency: a pooled analysis of two phase 3: What a 310-Participant Study Found Doxepin 3 mg has a statistically significant effect on sleep latency on the first night of treatment in adults with trouble sleeping that did not reach the clinical significance threshold. Sleep & breathing = Schlaf & Atmung • 2025-04-14 • Phase III Randomized Trial | N = 310 | 93/100 | PMID 40229607 ↗ |
| What the Latest Evidence Really Says About Different regimens of menopausal hormone therapy for improving sleep We identified a total of 3,059 studies and finally included 15 studies in the meta-analysis. Menopause (New York, N.Y.) • 2022-05-01 • Meta-Analysis | Multi-cohort | 92/100 | PMID 35102100 ↗ |
| Can This Approach Help? Inside the Latest Research on Low-sodium oxybate on diary-based sleep time in a clinical study in adults with Open-label LXB treatment in adults with idiopathic hypersomnia was associated with reductions in 24-hour TST, nocturnal TST, and total nap duration. Sleep medicine • 2026-02-15 • Phase III Randomized Trial | N = 148 | 88/100 | PMID 41442817 ↗ |
| Can This Approach Help? Inside the Latest Research on A minimal clinically important difference for the sleep inertia visual analog Establishing an MCID strengthens the SI-VAS value, adds context for findings related to sleep inertia in individuals with idiopathic hypersomnia from the phase 3 study, and aids clinicians in identifying clinically meaningful... Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine • 2025-07-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40135693 ↗ |
| Can This Approach Help? Inside the Latest Research on An efficacy, safety, and dose-response study of Ramelteon in patients with Ramelteon demonstrated a statistically significant reduction in LPS and a statistically significant increase in TST, with no apparent next-day residual effects, in patients with chronic primary trouble sleeping. Sleep medicine • 2006-01-15 • Randomized Controlled Trial | N = 107 | 88/100 | PMID 16309958 ↗ |
Hypersomnia Patient Community & “People Like Me” Threads
Filter Hypersomnia community threads and patient logs by age, biological sex, dosage, and treatment duration.